Celldex Therapeutics (CLDX) Gross Margin (2010 - 2026)
Celldex Therapeutics (CLDX) recorded quarterly Gross Margin of 9620.0% in Q1 2026, down 951.51% quarter-over-quarter from 914.88% in Q4 2025, and down 940806.0% on a YoY basis from N/an in Q1 2025.
Celldex Therapeutics (CLDX) Gross Margin (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Gross Margin history runs 7 years deep, the most recent figure standing at 9620.0% for Q1 2026.
- In Q1 2026, Gross Margin fell 940806.0% year-over-year to 9620.0%; the TTM figure through Mar 2026 stood at 510.51% (down 52490.0% YoY), while the FY2025 annual figure was 288.16%, down 30823.0% from the prior year.
- Gross Margin was 9620.0% for Q1 2026 at Celldex Therapeutics, down from 914.88% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 66.34% in Q3 2024 to a low of 9620.0% in Q1 2026.
- Historically, Gross Margin has averaged 1441.56% across 3 years, with a median of 161.72% in 2025.
- The sharpest annual moves came in 2025 and 2026: Gross Margin jumped 52652 bps in 2025, then tumbled 940806 bps in 2026.
- A 3-year view of Gross Margin shows it stood at 37.36% in 2024, then tumbled by 2349 bps to 914.88% in 2025, then tumbled by 952 bps to 9620.0% in 2026.
- The last three Gross Margin figures came in at 9620.0% (Q1 2026), 914.88% (Q4 2025), and 111.51% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Celldex Therapeutics | 2.16 Bn | 2.16 Bn | -1.44 Mn | -9,620.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9,620.00% |
| Dec 31, 2025 | -914.88% |
| Jun 30, 2025 | -111.51% |
| Mar 31, 2025 | -211.94% |
| Dec 31, 2024 | -37.36% |
| Sep 30, 2024 | 66.34% |
| Jun 30, 2024 | 35.35% |
| Mar 31, 2024 | -738.46% |
| Dec 31, 2013 | 100.00% |
| Sep 30, 2013 | 100.00% |
| Jun 30, 2013 | 100.00% |
| Mar 31, 2013 | 3.31% |
| Dec 31, 2012 | 2.63% |
| Sep 30, 2012 | 3.44% |
| Jun 30, 2012 | 6.77% |
| Mar 31, 2012 | 3.66% |
| Dec 31, 2011 | 3.08% |
| Sep 30, 2011 | 1.90% |
| Jun 30, 2011 | 0.56% |
| Mar 31, 2011 | 0.56% |